Patent application number | Description | Published |
20090036922 | SYSTEMS AND METHODS FOR CLOSING A TISSUE OPENING - The present invention is directed to tissue closure devices for closing a tissue opening, including one or more closure components, each closure component having a first member and a second member, each of the first and second members having a first surface that adheres to a tissue surface proximate to the tissue opening, each of the first and second members having a second surface substantially orthogonal to the first surface, and each of the first and second members having a transitional region between the first surface and the second surface which is contoured to evert an edge of the tissue opening upon the drawing together of the first and second members. The present invention is also directed to systems and kits, dressing systems, and methods for tissue repair and closure. | 02-05-2009 |
20120203273 | Systems and Methods for Closing a Tissue Opening - The present invention is directed to tissue closure devices for closing a tissue opening, including one or more closure components, each closure component having a first member and a second member, each of the first and second members having a first surface that adheres to a tissue surface proximate to the tissue opening, each of the first and second members having a second surface substantially orthogonal to the first surface, and each of the first and second members having a transitional region between the first surface and the second surface which is contoured to evert an edge of the tissue opening upon the drawing together of the first and second members. The present invention is also directed to systems and kits, dressing systems, and methods for tissue repair and closure. | 08-09-2012 |
20140058444 | Devices for Securely Closing Tissue Openings with Minimized Scarring - Devices, tools, systems, kits and methods for closing a tissue opening non-invasively are presented. The devices include a tissue closure device that reliably induces eversion of tissue edges that define a tissue opening. The devices may be used in combination with an applicator tool to provide easy and uniform apposition of the tissue closure devices across the tissue opening. Further embodiments provide for releasable locking of the tissue closure devices, allowing for drainage of wound edema and/or treatment of infection, without removal and reapplication of the devices. Still further embodiments allow for the passing of moisture or other substances that may collect under a tissue closure device. | 02-27-2014 |
20150018874 | SYSTEMS AND METHODS FOR CLOSING A TISSUE OPENING - Tissue closure devices include one or more closure components, each closure component having a first member and a second member, each of the first and second members having a first surface that adheres to a tissue surface proximate to the tissue opening, each of the first and second members having a second surface substantially orthogonal to the first surface, and each of the first and second members having a transitional region between the first surface and the second surface which is contoured to evert an edge of the tissue opening upon the drawing together of the first and second members. | 01-15-2015 |
Patent application number | Description | Published |
20100183632 | Antibody Therapy For Modulating Function Of Intestinal Receptors - The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition. | 07-22-2010 |
20100266607 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 10-21-2010 |
20120114653 | ANTIBODY THERAPY FOR TREATMENT OF DISEASES ASSOCIATED WITH GLUTEN INTOLERANCE - The present invention includes a pharmaceutical compositions and methods for treating diseases associated with gluten intolerance in a patient, comprising: administering to the patient an effective amount of an antibody having specific activity against gluten or gluten-derived peptides. Such diseases include, for example, celiac disease and dermatitis herpetiformis. | 05-10-2012 |
20120213796 | POLYCLONAL ANTIBODY COMPOSITIONS - The present invention provides purified immunoglobulin compositions derived from the colostrum of a bovine immunized with a target antigen. The immunoglobulin composition comprises polyclonal antibodies specific for the target antigen and is depleted of non-immunoglobulin factors. The invention includes methods of manufacturing the compositions of the invention. The invention further includes pharmaceutical formulations comprising a purified immunoglobulin composition of the invention and an optional pharmaceutically acceptable excipient. | 08-23-2012 |
20120258118 | ANTIBODY THERAPEUTICS WITH LOCAL ACTIVITY IN THE DIGESTIVE TRACT - This invention provides methods and compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been shown to be necessary for clinical benefit following systemic administration of antibody. This invention further describes therapeutic compositions of antibody therapeutics that are therapeutically effective in the digestive tract or below the mucosal barrier of the digestive tract but do not deliver levels of antibody to the systemic circulation that have been associated with adverse events and systemic immunosuppression following systemic administration of antibody. | 10-11-2012 |
20120315280 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 12-13-2012 |
20130045213 | ANTIBODY THERAPY FOR MODULATING FUNCTION OF INTESTINAL RECEPTORS AND METHODS OF TREATING DIABETES AND OBESITY - The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition. | 02-21-2013 |
20130058943 | BOVINE POLYCLONAL ANTIBODY SPECIFIC FOR HUMAN TNF - The invention provides a composition comprising polyclonal antibodies that specifically bind to with human tumor necrosis factor (hTNF) wherein the polyclonal antibodies are derived from the serum, milk or colostrum of a bovine animal that has been immunized hTNF or an immunogenic portion thereof. The antigenic specificity analysis of the anti-hTNF polyclonal antibodies of the invention is unique and has not been previously described for anti-hTNF polyclonal or monoclonal antibodies of the prior art. | 03-07-2013 |
20130084561 | BIODETECTION BY NUCLEIC ACID-TEMPLATED CHEMISTRY - The invention provides compositions and methods for the detection of biological targets, (e.g. nucleic acids and proteins) by nucleic acid templated chemistry, for example, by generating fluorescent, chemiluminescent and/or chromophoric signals. | 04-04-2013 |
20130303523 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION, PSYCHIATRIC DISORDERS, AND NEURODEGENERATIVE DISEASE - The present invention features, inter alia, pharmaceutically acceptable compositions that include metyrapol as the sole pharmaceutically active agent; compositions that include metyrapol and at least one additional pharmaceutically active agent; compositions in which the agent targeting the HPA axis is, itself, new or modified (e.g., a bi-specific antibody designed to traverse the blood-brain barrier or a known compound redesigned by, for example, conjugation to a substance that traverses the blood-brain barrier); and compositions in which the agent targeting the HPA axis is newly formulated in such a way that it fails to significantly inhibit cortisol production in the adrenal gland. For example, the composition can be formulated to include a dosage that is too low to reduce plasma cortisol levels or formulated to preferentially affect the skin. | 11-14-2013 |
20130324703 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 12-05-2013 |
20130337018 | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TRACT - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 12-19-2013 |
20140147446 | ANTIBODY THERAPY FOR MODULATING FUNCTION OF INTESTINAL RECEPTORS AND METHODS OF TREATING DIABETES AND OBESITY - The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition. | 05-29-2014 |
20140193467 | COMPOSITIONS COMPRISING TNF-SPECIFIC ANTIBODIES FOR ORAL DELIVERY - In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with increased stability within the environment of the digestive tract. Antibodies are described with enhanced permeability to a compromised digestive tract. | 07-10-2014 |
20150252106 | ANTIBODY THERAPY FOR MODULATING FUNCTION OF INTESTINAL RECEPTORS AND METHODS OF TREATING DIABETES AND OBESITY - The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition. | 09-10-2015 |
Patent application number | Description | Published |
20130182752 | System and Method for Detecting Burst Noise During Quadrature Amplitude Modulation Communications - A system and method for detecting burst noise during quadrature amplitude modulation (QAM) communications are provided. A QAM signal is acquired at a receiver in communication with a network. The QAM signal is demodulated at the receiver to identify a plurality of symbols. Amplitudes for each of the plurality of symbols are determined, and are compared to a predetermined threshold. For each amplitude that is greater than the predetermined threshold, information is recorded at the receiver relating to a burst noise event. The magnitude of the burst noise can be determined by measuring a difference between a received constellation point and a perimeter constellation point closest to the received constellation point. The information about the burst noise event can be transmitted to an error correction module for reducing future burst noise in the network. Equalizer coefficients and tracking loop performance can be adjusted/enhanced using the burst noise information. | 07-18-2013 |
20130272353 | SYSTEM AND METHOD FOR DYNAMIC PROFILE MANAGEMENT IN CABLE MODEM SYSTEMS - A system and method for dynamic profile management in a cable modem termination system (CMTS) is provided. A CMTS receiver is in communications with a plurality of cable modems, and a dynamic profile management module is in communication with the CMTS receiver. The dynamic profile management module establishes a communications profile for an upstream channel used by the CMTS receiver and at least one of the plurality of cable modems (the communications profile including a plurality of parameters associated with the upstream channel), continuously monitors performance metrics associated with communications across the upstream channel, and automatically adjusts the plurality of parameters of the communications profile in response to the monitored performance metrics. | 10-17-2013 |
20140185630 | Systems And Methods For Performing Fiber Node Splits Using Remote QAM Modulation And Demodulation - Systems and methods are provided for performing fiber node splits in DOCSIS cable systems by performing remote modulation and/or demodulation in the fiber node. In the downstream direction, a high-speed digital fiber optic interface can be used to send data from the CMTS to the fiber node, which then modulates the data onto separate downstream interfaces for subsequent distribution of the downstream data to CMs and/or STBs. In the upstream direction, different upstream interfaces from the CMs and/or STBs may be demodulated into digital streams which can then be combined into a single, time division multiplexed digital stream that is transmitted to the CMTS. As such, the modulation and demodulation functions are performed remotely in the fiber node instead of at the CMTS. This allows the fiber portion of the network to use less-expensive, off-the-shelf networking technologies such as Ethernet, and allows for more data to be sent over the fiber network such that additional fibers and/or wavelengths are not required when performing a node split. | 07-03-2014 |
Patent application number | Description | Published |
20120282249 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY - Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo. | 11-08-2012 |
20140341885 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY - Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo. | 11-20-2014 |
20140377251 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY - Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 anti body in vivo. | 12-25-2014 |
Patent application number | Description | Published |
20120088300 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM - Certain embodiments disclosed herein are directed to a method of producing endoderm cells, such as definitive endoderm cells by exposing stem cells such as embryonic stem cells or induced pluripotent stem (iPS) cells to an effective amount of at least one compound described herein to differentiate the stem cells into the endoderm cells such as definitive endoderm cells. Differentated endoderm cells produced by the methods disclosed herein can be differentiated into pancreatic epithelium, and other endoderm derivatives such as thymus, liver, stomach, intestine and lung. Another aspect of the present invention relates to a method of producing pancreatic progenitor cells, such as Pdx1-positive pancreatic progenitor cells by exposing endoderm cells, such as definitive endoderm cells to an effective amount of at least one compound described herein to differentiate the definitive endoderm cells into Pdx1-positive pancreatic progenitor cells. Kits and compositions comprising Pdx1-positive pancreatic progenitor produced using the methods are also described. | 04-12-2012 |
20140024114 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM - Certain embodiments disclosed herein are directed to a method of producing endoderm cells, such as definitive endoderm cells by exposing stem cells such as embryonic stem cells or induced pluripotent stem (iPS) cells to an effective amount of at least one compound described herein to differentiate the stem cells into the endoderm cells such as definitive endoderm cells. Differentiated endoderm cells produced by the methods disclosed herein can be differentiated into pancreatic epithelium, and other endoderm derivatives such as thymus, liver, stomach, intestine and lung. Another aspect of the present invention relates to a method of producing pancreatic progenitor cells, such as Pdx1-positive pancreatic progenitor cells by exposing endoderm cells, such as definitive endoderm cells to an effective amount of at least one compound described herein to differentiate the definitive endoderm cells into Pdx1-positive pancreatic progenitor cells. Kits and compositions comprising Pdx1-positive pancreatic progenitor produced using the methods are also described. | 01-23-2014 |
20150240213 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF DEFINITIVE ENDODERM - Certain embodiments disclosed herein are directed to a method of producing endoderm cells, such as definitive endoderm cells by exposing stem cells such as embryonic stem cells or induced pluripotent stem (iPS) cells to an effective amount of at least one compound described herein to differentiate the stem cells into the endoderm cells such as definitive endoderm cells. Differentiated endoderm cells produced by the methods disclosed herein can be differentiated into pancreatic epithelium, and other endoderm derivatives such as | 08-27-2015 |
Patent application number | Description | Published |
20150112403 | METHOD AND A SYSTEM FOR OPTIMIZING THE CONFIGURATION OF MULTISITE TRANSCRANIAL CURRENT STIMULATION AND A COMPUTER-READABLE MEDIUM - A system and a method for optimizing the configuration of multisite transcranial current stimulation, including providing an electric field characteristic target map on the brain's cortex, the target map including multiple cortical targets, the multiple cortical targets are localized and/or continuously varying and spatially extended, providing a weight map on the cortical surface prioritizing the important of areas in the target map for the purposes of optimization; and calculating, based on the target and weight maps, optimal currents and optimal locations for a plurality of electrodes intended for providing transcranial current stimulation to globally stimulate at once the multiple cortical targets with excitatory, inhibitory or neutral stimulation. | 04-23-2015 |
20150272468 | System And Method For Functional Brain Organization Mapping - Systems and method for producing functional brain organization maps are provided. The method includes providing functional connectivity magnetic resonance image (fcMRI) data, a population atlas, a variation map indicative of inter-subject variability in the atlas. The method also includes initializing a subject map using the atlas, determining a reference signal for each functional connectivity network in the subject map using signals derived from the fcMRI data, computing correlations between the signals and reference signal of each functional connectivity network, and iteratively updating the subject map by reassigning locations in the subject brain when correlating with a functional connectivity network, updating at each iteration the reference signal using the subject map, the population atlas, the variation map, and the set of fcMRI data. The method further includes generating a report indicative of a functional brain organization for the brain of the subject using the subject map. | 10-01-2015 |
Patent application number | Description | Published |
20110131888 | BONDED ABRASIVE ARTICLE AND METHOD OF FORMING - An abrasive article includes an abrasive body having abrasive grains within a bond material, the abrasive body further including a spinel material disposed at an interface between the abrasive grains and the bond matrix. | 06-09-2011 |
20120247027 | ABRASIVE ARTICLE FOR HIGH-SPEED GRINDING OPERATIONS - An abrasive article includes a bonded abrasive body having abrasive particles comprising microcrystalline alumina (MCA) contained within a bond material. In an embodiment, the bonded abrasive body has a strength ratio (MOR/MOE) of at least about 0.80. | 10-04-2012 |
20120297692 | ABRASIVE ARTICLE FOR HIGH-SPEED GRINDING OPERATIONS - An abrasive article can include a bonded abrasive body having abrasive particles comprising microcrystalline alumina (MCA) contained within a bond material. In an embodiment, the bonded abrasive body has a porosity of at least about 42 vol % of the total volume of the bonded abrasive body. Additionally, in an embodiment, the bonded abrasive body is capable of grinding a workpiece comprising metal at a speed of at least about 60 m/s at a material removal rate of at least about 0.4 in | 11-29-2012 |
20130152482 | ABRASIVE ARTICLE FOR ULTRA HIGH MATERIAL REMOVAL RATE GRINDING OPERATIONS - An abrasive article including a bonded abrasive body having a bond material present in an amount of not greater than about 15 vol % for the total volume of the body, abrasive particulate material contained in the bond material, the abrasive particulate material including abrasive agglomerates and unagglomerated abrasive particles, wherein the body comprises an abrasive particulate ratio (APp:APagg) within a range between 3:1 and about 1:3, wherein APp represents the amount (vol %) of unagglomerated abrasive particles present in the body and APagg represents the amount (vol %) of abrasive agglomerates present in the body, and a porosity of at least about 42 vol % of the total volume of the bonded abrasive body. | 06-20-2013 |
20140007517 | Abrasive Article for Lower Speed Grinding Operations - An abrasive article includes a bonded abrasive body having abrasive particles contained within a bond material. The bonded abrasive body may include an abrasive particle-to-bond material interfacial modulus of elasticity (MOE) of at least about 225 GPa. The bonded abrasive body may be configured to grind a workpiece comprising metal at a speed of less than about 60 m/s. | 01-09-2014 |